• 1
    Dmochowski R, Chapple C, Nitti VW et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 2010; 184: 24162422
  • 2
    Tincello DG, Kenyon S, Abrams KR et al. Botulinum toxin A versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). Eur Urol 2012; 62: 507514
  • 3
    Brubaker L, Richter HE, Visco A et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008; 180: 217222
  • 4
    Rajkumar GN, Small DR, Mustafa AW, Conn G. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int 2005; 96: 848852
  • 5
    Herschorn S, Gajewski J, Ethans K et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol 2011; 185: 22292235
  • 6
    Anger JT, Weinberg A, Suttorp MJ, Litwin MS, Shekelle PG. Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: a systematic review of the literature. J Urol 2010; 183: 22582264
  • 7
    Manecksha RP, Cullen IM, Ahmad S et al. Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity. Eur Urol 2012; 61: 928935
  • 8
    Duthie J, Wilson DI, Herbison GP, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev 2007; (3): CD005493
  • 9
    Stoehrer M, Wolff A, Kramer G et al. Treatment of neurogenic detrusor overactivity with botulinum toxin A: the first seven years. Urol Int 2009; 83: 379385
  • 10
    Grosse J, Kramer G, Stohrer M. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005; 47: 653659
  • 11
    Sampaio C, Costa J, Ferreira JJ. Clinical comparability of marketed formulations of botulinum toxin. Mov Disord 2004; 19 (Suppl. 8): S129136
  • 12
    Kollewe K, Mohammadi B, Dengler R, Dressler D. Hemifacial spasm and reinnervation synkinesias: long-term treatment with either Botox or Dysport. J Neural Transm 2010; 117: 759763
  • 13
    Karsai S, Adrian R, Hammes S, Thimm J, Raulin C. A randomized double-blind study of the effect of Botox and Dysport/Reloxin on forehead wrinkles and electromyographic activity. Arch Dermatol 2007; 143: 14471449
  • 14
    Van den Bergh PY, Lison DF. Dose standardization of botulinum toxin. Adv Neurol 1998; 78: 231235
  • 15
    Albanese A. Terminology for preparations of botulinum neurotoxins: what a difference a name makes. JAMA 2011; 305: 8990
  • 16
    Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167178
  • 17
    Jackson B, Burge F, Bronjewski E, Parkinson RJ. Intravesical botulinum toxin for overactive bladder syndrome without detrusor overactivity. Br J Med Surg Urol 2012; 5: 169173
  • 18
    Brisinda G, Albanese A, Cadeddu F et al. Botulinum neurotoxin to treat chronic anal fissure: results of a randomized ‘Botox vs Dysport’ controlled trial. Aliment Pharmacol Ther 2004; 19: 695701
  • 19
    Costa J, Espirito-Santo C, Borges A et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev 2005; (1): CD003633
  • 20
    Bauer RM, Gratzke C, Roosen A et al. Patient-reported side effects of intradetrusor botulinum toxin type a for idiopathic overactive bladder syndrome. Urol Int 2011; 86: 6872
  • 21
    Jeffery S, Fynes M, Lee F, Wang K, Williams L, Morley R. Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. BJU Int 2007; 100: 13021306
  • 22
    Manecksha RP, Redmond P, Siddiqui K, Creagh T. Experience with Intradetrusor Injection of Botulinum-A Toxin for the Treatment of Idiopathic Detrusor Overactivity in a Single Irish Institution. Curr Urol 2008; 2: 6266
  • 23
    Kessler TM, Ryu G, Burkhard FC. Clean intermittent self-catheterization: a burden for the patient? Neurourol Urodyn 2009; 28: 1821
  • 24
    Wyndaele JJ. Complications of intermittent catheterization: their prevention and treatment. Spinal Cord 2002; 40: 536541
  • 25
    Mohee A, Khan A, Harris N, Eardley I. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int 2012; 111: 106113
  • 26
    Sahai A, Sangster P, Kalsi V, Khan MS, Fowler CJ, Dasgupta P. Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable? BJU Int 2009; 103: 630634